LATEST UPDATES » Vol 24, No. 08, August 2020 – Unravelling the Mysteries of the Human Brain       » Reducing Blood Sugar with Tea Leaves in Type 2 Diabetic Rats       » Generating Clean Water from Solar-Powered Technology       » COVID-19 Diagnostic Kits: The Singapore Story       » Fighting for Sustainability: One Shrimp at a Time       » Creating Robotic Systems with Vision and Touch Sensors      
Vol 24, No. 07, July 2020   |   Issue PDF view/purchase
Approval of Enzalutamide for the Treatment of Prostate Cancer in Japan
The Japan Ministry of Health, Labour and Welfare (MHLW) approves the use of XTANDI® (enzalutamide) by Astellas Pharma Inc., for the treatment of prostate cancer with distant metastasis.

XTANDI® (enzalutamide) is an oral androgen receptor signalling inhibitor, for the treatment of prostate cancer patients with distant metastasis. With this approval, XTANDI is now indicated for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC), a form of prostate cancer that has spread to other parts of the body and still responds to a medical or surgical treatment that lowers testosterone. This is in addition to an existing indication for castration-resistant prostate cancer (CRPC).

This approval is based on results from the ARCHES trial, a randomised multi-national Phase III study evaluating enzalutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT in 1,150 men with mHSPC. This trial met its primary endpoint of radiographic progression-free survival (rPFS).

Data from the ENZAMET trial also supported the result which was a Phase III trial that studied enzalutamide plus ADT versus ADT plus a standard nonsteroidal antiandrogen therapy (bicalutamide, nilutamide or flutamide) in men with mHSPC.

The ARCHES trial demonstrated a reduced risk of radiographic progression or death by 61 percent for those with enzalutamide plus ADT compared to a placebo plus ADT in men with mHSPC.

The safety analyses of the ARCHES and ENZAMET trials were generally consistent with the safety profile of enzalutamide in previous clinical trials in CRPC. In the ARCHES trial, adverse drug reactions were reported in 53 percent of patients. Major adverse drug reactions with an incidence of more than 10% were hot flush (20.5%) and fatigue (14.9%). In the ENZAMET trial, serious adverse drug reactions were reported in 3 percent of patients. Serious adverse drug reactions observed in two or more patients were seizure (0.9%), hypertension (0.5%) and fatigue (0.4%).

“The MHLW approval of XTANDI marks continued progress to provide a treatment option to men earlier in their advanced prostate cancer treatment journey,” said Andrew Krivoshik, M.D., Ph.D., Senior Vice President and Global Therapeutic Area Head, Oncology Development. “At Astellas, we have made a commitment to fight cancer and continue to build a robust oncology portfolio to help meet the needs of patients.”


news Proteona Honoured with "one to watch" Prize in the Inaugural Spinoff Prize by Nature Research and Merck Grou
news Twist Bioscience and Proteona Join Hands to Protect Immunocompromised Patients from COVID-19 Infection
news Meeting Demand for Respiratory Ventilators Amid COVID-19 Pandemic
news Innovation in Healthcare: IOT-Enabled Tele-Ventilators to Fight Against the COVID-19 Pandemic

About Us
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
Copyright© 2020 World Scientific Publishing Co Pte Ltd  •  Privacy Policy